Gastrointestinale Stromatumoren (GIST)

Schlüsselwörter

gastrointestinale Stromatumoren - GIST

Keywords

gastrointestinal stromal tumors - GIST

• Literatur

• 1 Blay JY, Shen L, Kang YK. Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST). J Clin Oncol 2013; 31 (Suppl. 01) abstr 10501
• 2 Corless CL, Ballman KV, Antonescu C et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol 2010; 28 (Suppl. 01) abstr 10006
• 3 Demetri GD, Jeffers M, Reichardt P. Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes. J Clin Oncol 2013; 31 (Suppl. 01) abstr 10503
• 4 Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295-302
• 5 ESMO / European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 07) vii49-vii55
• 6 Fletcher CDM, Berman JJ, Gorless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465
• 7 George S, Wang Q, Heinrich MC et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012; 30: 2401-2407
• 8 Joensuu H, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor. JAMA 2012; 307: 1265-1272
• 9 Joensuu H, Vehtari A, Riihimäki J et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13: 265-274
• 10 Li J, Gong FJ, Wu AW et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011; 37: 319-324
• 11 Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83
• 12 Reichardt P, Blay JY, Boukovinas I et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol 2012; 23: 2776-2781
• 13 Reichardt P, Blay JY, Gelderblom H et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012; 23: 1680-1687
• 14 von Bubnoff N, Kerle I, Specht K. Detection of mutant-free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor (GIST) harboring activating mutations of C-Kit or PDGFRA. J Clin Oncol 2013; 31 (Suppl. 01) abstr 10508